Project Grant K23HL175213
Award Date
9/1/24
Completion Date
7/31/29
Dollars Obligated
$189K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,107,276 to Lasarrus Clinic And Research Center Inc. to develop a mobile health system for remote monitoring of patients with Chronic Obstructive Pulmonary Disease (COPD). The project aims to enhance patient adherence to remote monitoring and early symptom recognition, in order to reduce COPD readmissions and healthcare costs. The system utilizes a wearable...
This $1,644,550 Cooperative Agreement award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to understand how interactions between epithelial, mesenchymal, and matrix compartments drive progressive fibrosis in interstitial lung diseases (ILD). The award will fund a multidisciplinary team from the University of California, Los Angeles (UCLA) to use spatial transcriptomics, single-cell secretion analysis, and regional proteomics...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research provides $695,421 to The Regents of the University of California, San Francisco (UCSF) to conduct research focused on reversing pathogenic remodeling in idiopathic pulmonary fibrosis (IPF). The key objectives are to define pro-reparative differentiation pathways in the fibroblast and stem cell compartments that can be leveraged as therapy, and...
This federal Project Grant award of $805,845 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and testing of novel lung-targeted therapeutic delivery systems. The goal is to create "precision drug delivery systems" that can actively transport anti-fibrotic agents directly into lung tissue to treat conditions like idiopathic pulmonary fibrosis. Key products/services include engineering...
This $110,959 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the mechanisms driving the transition of lipofibroblasts to myofibroblasts in systemic sclerosis, a rare autoimmune fibrosing disease with high mortality. The research aims to define the role of the genes PER3 and CD36 in regulating the lipofibroblast to myofibroblast transition, which is a key driver...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $771,751 to The University of Texas Southwestern Medical Center to investigate the prognostic and predictive impact of telomere length in fibrotic interstitial lung disease (ILD). The 5-year project aims to: 1) quantify age-adjusted telomere length thresholds that inform differential progression and mortality risk in ILD patients;...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is providing $1,147,992 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at advancing precision medicine for acute respiratory distress syndrome (ARDS) and sepsis. The key focus is on deeply phenotyping human samples to understand the functional immune response and pathogen drivers of...
This Project Grant award of $1,331,984.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to develop new lung quantitative ultrasound (LQUS) metrics for monitoring pulmonary edema due to heart failure and idiopathic pulmonary fibrosis. The primary awardee, North Carolina State University, will work to mitigate chest-wall effects, optimize data acquisition, and apply LQUS methods in human patients with heart failure and...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $196,245 to the Regents of the University of Michigan to develop predictive biomarkers for treatment failure in patients with connective tissue disease-associated interstitial lung disease (CTD-ILD). The primary objectives are to: 1) determine forced vital capacity (FVC) trajectories and cumulative incidence of treatment failure across CTD-ILD subtypes; 2)...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $117,750 to the Ann & Robert H Lurie Children's Hospital of Chicago to develop and validate the use of wireless biosensors and a portable capnograph device for remote patient monitoring of children on long-term invasive home mechanical ventilation. The project aims to address limitations of the hospital's current hand-collected vital sign data approach by...